LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the fourth quarter and fiscal year 2024, ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced a strategic loan and security agreement with Hercules Capital, Inc. ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Swiss National Bank lessened its position in shares of Savara Inc (NASDAQ:SVRA – Free Report) by 6.7% during the fourth ...

SAVARA ($SVRA) is expected to release its quarterly earnings data on Wednesday, April 2nd after market close, per Finnhub. Analysts are expecting revenue of $0 and ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Savara (SVRA – Research Report) yesterday and set a price target of $3.00. The ...

Savara Inc (NASDAQ:SVRA – Free Report) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Savara in a note issued to investors on Friday ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement ...

Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company focused on developing novel therapies for rare respiratory diseases, is approaching a critical juncture in its journey to bring its lead ...

As of December 31, 2024, the company had cash, cash equivalents and short-term investments of $196.3M. “Completing submission of the BLA is an ...

LANGHORNE, Pa., March 26, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it ...